Quick Answer
Calidi Biotherapeutics, Inc. reported Stockholders Equity of $3.76 million for fiscal year 2025.
Calidi Biotherapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $3.76M | +145.0% |
| 2024 | $1.53M | +118.6% |
| 2023 | -$8.23M | +83.7% |
| 2022 | -$50.44M | -59.6% |
| 2021 | -$31.61M | — |
| 2021 | $0.00 | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $6.92M | +170.6% | +292.2% |
| June 30, 2025 | $1.76M | +115.0% | -74.6% |
| March 31, 2025 | $6.94M | +147.6% | +352.5% |
| December 31, 2024 | $1.53M | +118.6% | +115.7% |
| September 30, 2024 | -$9.80M | -795.6% | +16.6% |
| June 30, 2024 | -$11.75M | +81.6% | +19.4% |
| March 31, 2024 | -$14.57M | +73.6% | -77.0% |
| December 31, 2023 | -$8.23M | +83.7% | -652.7% |
- Calidi Biotherapeutics, Inc. showed an increase of +145.0% in Stockholders Equity compared to the prior fiscal year.
- The most recent figure is from Calidi Biotherapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: